Related Experiment Video

Updated: Aug 15, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K

Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option

Alessandro Maloberti1,2, Saverio Fabbri2, Valentina Colombo2

  • 1Cardiology 4, Cardio Center A. De Gasperis, ASST GOM Niguarda, 20162 Milan, Italy.

International Journal of Molecular Sciences
|January 8, 2023
PubMed

Insights

High Lipoprotein(a) levels significantly increase cardiovascular disease risk. New therapies targeting Lipoprotein(a) show promise for managing atherosclerosis and aortic stenosis, offering hope for high-risk patients.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Atherosclerosis is a chronic inflammatory disease with late clinical manifestations.
  • Early identification and intensive risk factor management are crucial for preventing atherosclerotic lesions.
  • Lipoprotein(a) [Lp(a)] is a newly identified marker strongly associated with increased cardiovascular disease risk.

Purpose of the Study:

  • To review the role of Lp(a) in cardiovascular diseases and aortic stenosis.
  • To discuss the synthesis, clearance, and measurement of Lp(a).
  • To explore emerging therapeutic strategies for reducing Lp(a) levels and their clinical impact.

Main Methods:

  • Review of epidemiological studies, mendelian randomization, and genome-wide association studies.
  • Analysis of meta-analyses demonstrating the link between Lp(a) and cardiovascular risk.
  • Examination of recent findings on Lp(a)'s association with aortic stenosis.

Main Results:

  • High Lp(a) levels are consistently linked to a very high risk of future cardiovascular diseases.
  • Lp(a) has a newly identified association with aortic stenosis.
  • Specific drugs effectively reduce circulating Lp(a) levels, with ongoing trials evaluating their CV event reduction capacity.

Conclusions:

  • Lp(a) is a critical, actionable risk factor for cardiovascular disease and aortic stenosis.
  • Novel therapeutic interventions targeting Lp(a) are on the horizon.
  • Future research will clarify the clinical benefit of Lp(a)-lowering therapies in preventing cardiovascular events.

Keywords:
aortic stenosiscardiovascular eventslipoprotein(a)

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
18
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
745
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
34
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
32
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
242